SCYNEXIS Inc (NASDAQ:SCYX) has been assigned a consensus rating of “Buy” from the eight brokerages that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $10.00.

Several research analysts have recently commented on SCYX shares. Zacks Investment Research cut shares of SCYNEXIS from a “buy” rating to a “hold” rating in a report on Tuesday, September 12th. Guggenheim started coverage on shares of SCYNEXIS in a report on Tuesday, October 24th. They set a “buy” rating and a $6.00 target price on the stock. Finally, ValuEngine raised shares of SCYNEXIS from a “strong sell” rating to a “sell” rating in a report on Saturday, December 9th.

Shares of SCYNEXIS (NASDAQ:SCYX) traded down $0.08 on Tuesday, hitting $1.98. 164,973 shares of the stock traded hands, compared to its average volume of 250,328. SCYNEXIS has a 12 month low of $1.52 and a 12 month high of $3.82. The company has a market capitalization of $56.55, a PE ratio of -2.44 and a beta of 0.36. The company has a debt-to-equity ratio of 0.43, a current ratio of 7.30 and a quick ratio of 7.30.

A number of large investors have recently made changes to their positions in SCYX. GSA Capital Partners LLP increased its stake in SCYNEXIS by 33.7% in the second quarter. GSA Capital Partners LLP now owns 176,700 shares of the company’s stock valued at $316,000 after acquiring an additional 44,500 shares during the last quarter. Vanguard Group Inc. increased its stake in SCYNEXIS by 6.0% in the second quarter. Vanguard Group Inc. now owns 868,394 shares of the company’s stock valued at $1,554,000 after acquiring an additional 48,978 shares during the last quarter. DAFNA Capital Management LLC increased its stake in SCYNEXIS by 32.7% in the second quarter. DAFNA Capital Management LLC now owns 506,900 shares of the company’s stock valued at $907,000 after acquiring an additional 125,000 shares during the last quarter. National Asset Management Inc. bought a new position in SCYNEXIS in the second quarter valued at approximately $551,000. Finally, Dimensional Fund Advisors LP bought a new position in SCYNEXIS in the third quarter valued at approximately $264,000. 30.90% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “SCYNEXIS Inc (SCYX) Receives Consensus Rating of “Buy” from Analysts” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.watchlistnews.com/scynexis-inc-scyx-receives-consensus-rating-of-buy-from-analysts/1800422.html.

About SCYNEXIS

SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.

Analyst Recommendations for SCYNEXIS (NASDAQ:SCYX)

Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with Analyst Ratings Network's FREE daily email newsletter.